CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO) Files An 8-K Other Events
Item 8.01. Other Events.

As previously disclosed, on April 12, 2017, Catalyst Biosciences, Inc. (the “Company”) completed a public offering of its securities. As of April 20, 2017, the Company had outstanding 4,260,161 shares of Common Stock and 5,750 shares of Series A Preferred Stock (convertible into an aggregate of 1,150,000 shares of Common Stock).

About CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO)

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.

CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO) Recent Trading Information

CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO) closed its last trading session down -0.38 at 4.56 with 379,476 shares trading hands.